183 related articles for article (PubMed ID: 27620743)
21. Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells.
Fouad MA; Sayed-Ahmed MM; Huwait EA; Hafez HF; Osman AM
BMC Pharmacol Toxicol; 2021 Jan; 22(1):8. PubMed ID: 33509300
[TBL] [Abstract][Full Text] [Related]
22. Vitamin E-based micelles enhance the anticancer activity of doxorubicin.
Danhier F; Kouhé TT; Duhem N; Ucakar B; Staub A; Draoui N; Feron O; Préat V
Int J Pharm; 2014 Dec; 476(1-2):9-15. PubMed ID: 25245548
[TBL] [Abstract][Full Text] [Related]
23. Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo.
Xu HB; Shen ZL; Fu J; Xu LZ
Phytomedicine; 2014 Sep; 21(11):1221-9. PubMed ID: 25172783
[TBL] [Abstract][Full Text] [Related]
24. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics.
Chekhun VF; Borikun TV; Lukianova NY
Exp Oncol; 2016 Mar; 38(1):26-30. PubMed ID: 27031715
[TBL] [Abstract][Full Text] [Related]
25. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
[TBL] [Abstract][Full Text] [Related]
26. Luteolin attenuates doxorubicin-induced cytotoxicity to MCF-7 human breast cancer cells.
Sato Y; Sasaki N; Saito M; Endo N; Kugawa F; Ueno A
Biol Pharm Bull; 2015; 38(5):703-9. PubMed ID: 25947916
[TBL] [Abstract][Full Text] [Related]
27. 2-Methoxyestradiol reverses doxorubicin resistance in human breast tumor xenograft.
Azab SS; Salama SA; Hassan MH; Khalifa AE; El-Demerdash E; Fouad H; Al-Hendy A; Abdel-Naim AB
Cancer Chemother Pharmacol; 2008 Oct; 62(5):893-902. PubMed ID: 18253735
[TBL] [Abstract][Full Text] [Related]
28. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride.
Chen YY; Li ZZ; Ye YY; Xu F; Niu RJ; Zhang HC; Zhang YJ; Liu YB; Han BS
BMC Mol Biol; 2016 Mar; 17():6. PubMed ID: 26935744
[TBL] [Abstract][Full Text] [Related]
30. Proteomics reveals protein profile changes in doxorubicin--treated MCF-7 human breast cancer cells.
Chen ST; Pan TL; Tsai YC; Huang CM
Cancer Lett; 2002 Jul; 181(1):95-107. PubMed ID: 12430184
[TBL] [Abstract][Full Text] [Related]
31. A combined treatment TNF-alpha/doxorubicin alleviates the resistance of MCF-7/Adr cells to cytotoxic treatment.
Cao W; Ma SL; Tang J; Shi J; Lu Y
Biochim Biophys Acta; 2006 Feb; 1763(2):182-7. PubMed ID: 16483679
[TBL] [Abstract][Full Text] [Related]
32. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
33. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of human breast carcinoma MCF-7 cells differing in their resistance to doxorubicin: effect of ionizing radiation on apoptosis and TGF-beta production.
Chorna I; Bilyy R; Datsyuk L; Stoika R
Exp Oncol; 2004 Jun; 26(2):111-7. PubMed ID: 15273662
[TBL] [Abstract][Full Text] [Related]
35. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
[TBL] [Abstract][Full Text] [Related]
36. Synergistically Enhanced Therapeutic Effect of a Carrier-Free HCPT/DOX Nanodrug on Breast Cancer Cells through Improved Cellular Drug Accumulation.
Chen F; Zhao Y; Pan Y; Xue X; Zhang X; Kumar A; Liang XJ
Mol Pharm; 2015 Jul; 12(7):2237-44. PubMed ID: 25996761
[TBL] [Abstract][Full Text] [Related]
37. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro.
Kurbacher CM; Wagner U; Kolster B; Andreotti PE; Krebs D; Bruckner HW
Cancer Lett; 1996 Jun; 103(2):183-9. PubMed ID: 8635156
[TBL] [Abstract][Full Text] [Related]
38. Synergistic antitumoral effect of combination E gene therapy and Doxorubicin in MCF-7 breast cancer cells.
Rama AR; Prados J; Melguizo C; Burgos M; Alvarez PJ; Rodriguez-Serrano F; Ramos JL; Aranega A
Biomed Pharmacother; 2011 Jul; 65(4):260-70. PubMed ID: 21723082
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin.
Liu Y; Du F; Chen W; Yao M; Lv K; Fu P
Exp Cell Res; 2013 Dec; 319(20):3140-9. PubMed ID: 24012960
[TBL] [Abstract][Full Text] [Related]
40. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
